ReviewInternational journal of molecular sciences2021
SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07700940 (Does The Positive Reno-Protective Effect Of Sodium Glucose Co-Transporter 2 Inhibitors Extend To Lupus Nephritis Population?), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Does The Positive Reno-Protective Effect Of Sodium Glucose Co-Transporter 2 Inhibitors Extend To Lupus Nephritis Population?
Who cites it
22 citing papers in PubMed.
- SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function.Clinical journal of the American Society of Nephrology : CJASN · 2022Trial
- Real-World Experience With Dapagliflozin in Non-diabetic Chronic Kidney Disease: A Case Series From India.Cureus · 2026Article
- SGLT2 Inhibitors and Long-Term Outcomes After AKI.Kidney international reports · 2026Article
- Sodium-Glucose Cotransporter 2 Inhibitors in Patients Undergoing Coronary Angiography: A Randomized Controlled Trial (BELIEVE Trial).Kidney360 · 2025Article
- Asymptomatic Hyperuricemia and the Kidney: Lessons from the URRAH Study.Metabolites · 2025Review
- Efficacy and safety of dapagliflozin in children with kidney disease: real-world data.Pediatric nephrology (Berlin, Germany) · 2024Article
- Canagliflozin attenuates kidney injury, gut-derived toxins, and gut microbiota imbalance in high-salt diet-fed Dahl salt-sensitive rats.Renal failure · 2024Article
- Type 2 Diabetes and Chronic Kidney Disease: An Opportunity for Pharmacists to Improve Outcomes.Journal of clinical medicine · 2024Review
- Efficacy and Safety of Adding Empagliflozin to Liraglutide on Renal Function in Patients with Advanced-Stage Type 2 Diabetic Kidney Disease: A Randomized Controlled Trial.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Multifaceted relationship between diabetes and kidney diseases: Beyond diabetes.World journal of diabetes · 2023Review
- The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetes.The Lancet regional health. Europe · 2023Article
- Non-Haemodynamic Mechanisms Underlying Hypertension-Associated Damage in Target Kidney Components.International journal of molecular sciences · 2023Review
- Update on Diabetic Kidney Disease (DKD): Focus on Non-Albuminuric DKD and Cardiovascular Risk.Biomolecules · 2023Review
- The effect of dapagliflozin on uric acid excretion and serum uric acid level in advanced CKD.Scientific reports · 2023Article
- The Effect of SGLT2 Inhibitors on the Development of Contrast-Induced Nephropathy in Diabetic Patients with Non-ST Segment Elevation Myocardial Infarction.Medicina (Kaunas, Lithuania) · 2023Article
- Addressing kidney health disparities with new national policy: the time is now.Cardiovascular diagnosis and therapy · 2023Review
- The Neurohormonal Overactivity Syndrome in Heart Failure.Life (Basel, Switzerland) · 2023Article
- Narrative review investigating the nephroprotective mechanisms of sodium glucose cotransporter type 2 inhibitors in diabetic and nondiabetic patients with chronic kidney disease.Frontiers in endocrinology · 2023Review
- Emerging Role of Sodium-Glucose Co-Transporter 2 Inhibitors for the Treatment of Chronic Kidney Disease.International journal of nephrology and renovascular disease · 2023Review
- Clinical studies of dapagliflozin in pediatric patients: a rapid review.Annals of pediatric endocrinology & metabolism · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, following the publication of results from several RCTs, first on cardiovascular and more recently on renal outcomes, SGLT2is have become the standard of care to prevent diabetic kidney disease and slow its progression. This narrative review focuses on biological mechanisms, both renal and extrarenal, underlying kidney protection with SGLT2is. Furthermore, data from cardiovascular as well as renal outcome trials, mostly conducted in diabetic patients, are presented and discussed to provide an overview of current uses as well as the future therapeutic potential of these drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.